Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.70 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201868 | 1.00 | CYP19A1 (0.70) | CYP19A1LIG1CXCR3CHRM1KDM1A | |
| SCHEMBL8245665 | 1.00 | CYP19A1 (0.70) | CYP19A1LIG1CXCR3CHRM1KDM1A | |
| SCHEMBL14520901 | 0.84 | CYP19A1 (0.72) | CYP19A1CXCR3CRBN | |
| SCHEMBL4556388 | 0.84 | CYP19A1 (0.72) | CYP19A1CXCR3CRBN | |
| SCHEMBL10530941 | 0.82 | CYP19A1 (1.00) | CYP19A1 | |
| Cyproximide SCHEMBL121879 | 0.82 | CYP19A1 (0.70) | CYP19A1LIG1CXCR3KDM1ARCOR1 | |
| SCHEMBL10530071 | 0.82 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL22623727 | 0.82 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL1552771 | 0.81 | CYP19A1 (0.69) | CYP19A1CXCR3KDM1AMMP2MMP9 | |
| SCHEMBL2054565 | 0.81 | CYP19A1 (0.69) | CYP19A1CXCR3KDM1AMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917013-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| EP-1891057-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-02-27 | — | — | EP | disclosed |
| EP-1869018-A1 | 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006133946-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006108700-A1 | 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |